PDGFRB and neoplasm: Sorafenib (Sora) is the first Food and Drug Administration–approved targeted drug for advanced HCC.3, 4, 5 As a multiple-target kinase inhibitor, Sora suppresses tumor cell proliferation by inhibiting the activity of the intracellular serine/threonine kinases Ras/Raf/MEK/ERK and blocks tumor angiogenesis by targeting the cell surface tyrosine kinase receptors VEGFR, PDGFR, c-KIT, and FLT-3.6